There's a good reason that I always include the warning that small-cap med-techs carry above average risks, and LipoScience (NASDAQ:LPDX) dutifully provided an example last week. Due in part to system placement delays and delays in ramping up new sales reps, this emerging diagnostics company missed expectations for the first quarter and lowered guidance for the rest of the year.
Retribution was swift and severe - the shares tanked 25% in a single day. Now the question for investors is whether there is still an opportunity here and where it's worth the risks to buy shares in the hopes of realizing that opportunity.
A Multi-Factor Miss In Q1
The first quarter wasn't a banner quarter for the diagnostics...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|